News & Events
FDA expands clinical trials of prototype coronavirus vaccines
- April 9, 2020
- Posted by: Wiley M. Wagner
- Category: Science
This photo taken on January 30, 2020 shows medical staff members wearing facemasks talking at a hospital in Wuhan in China's central Hubei province, during the virus outbreak in the city. – The World Health Organization declared a global emergency over the new coronavirus, as China reported January 31 the death toll had climbed to 213 with nearly 10,000 infections. (Photo by STR / AFP) / China OUT (Photo by STR / AFP via Getty Images)
The new type of coronavirus COVID-19 continues to terrorize the world and the scientific community, despite the fact that its genome has already been fully isolated and investigated. Today, representatives of the US Federal Food and Drug Administration Quality Control Commission presented the results of their initial study, according to which the Commissioners gave the go-ahead for further research in the direction of cure for coronavirus. In this case, we are talking about the use of two types of so-called research therapies – the use of convalescent plasma and hyperimmune globulin, each of which is taken from human blood.
More precisely, from the blood of those people who had been ill with the coronavirus and subsequently recovered without showing any dangerous side effects. The use of blood plasma from people who have previously been ill with coronavirus from the very beginning was considered by the FDA as the most reliable and effective way to develop a universal and safe vaccine for Chinese coronavirus, although there are some difficulties here, primarily the inability to find the appropriate reagents to activate the antiviral effect.
It is worth noting that at this stage, FDA experts consider the use of more hyperimmune globulin, released in the blood of coronavirus survivors, as the most effective candidate for this antiviral effect. In connection with the continuation of clinical trials of new vaccine prototypes based on these approaches, the Commission calls for donating blood plasma in medical institutions as often as possible and in order to enrich the existing fund for treating patients.
It is worth noting that, until now, the use of these plasma natural reagents has not been considered a real way to cure, however, if preliminary clinical trials of a new vaccine prototype show a positive result, then most likely you can count on a really positive trend and a tendency to cure a new coronavirus type.